Phase 3 Data: Galderma’s Nemolizumab Improves Itch, Skin Lesions, and Sleep Disturbance in AD
Galderma’s IL- 31 blocker nemolizumab performed well in the phase III ARCADIA 1 and 2 atopic dermatitis (AD) trials. Nemolizumab is a first-in-class monoclonal antibody that inhibits the signaling of IL-31, a neuroimmune cytokine known to drive key signs and symptoms of AD. In the ARCADIA trials, AD patients saw statistically significant improvements in as […]